MX2021013938A - Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer. - Google Patents

Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer.

Info

Publication number
MX2021013938A
MX2021013938A MX2021013938A MX2021013938A MX2021013938A MX 2021013938 A MX2021013938 A MX 2021013938A MX 2021013938 A MX2021013938 A MX 2021013938A MX 2021013938 A MX2021013938 A MX 2021013938A MX 2021013938 A MX2021013938 A MX 2021013938A
Authority
MX
Mexico
Prior art keywords
cancer
methods
prediction
compositions
therapeutic efficacy
Prior art date
Application number
MX2021013938A
Other languages
English (en)
Inventor
Özlem Türeci
Daniel Maurus
Ugur Sahin
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2021013938A publication Critical patent/MX2021013938A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere en general a métodos y composiciones para la predicción de la eficacia terapéutica de tratamientos contra el cáncer y la prognosis de cáncer. La invención describe marcadores que se asocian con resultados favorables y desfavorables, respectivamente, en ciertos tratamientos contra el cáncer y son útiles como marcadores de pronóstico para el cáncer. Los métodos que implican estos marcadores se describen para predecir el beneficio de la terapia de cáncer y pronosticar el resultado clínico para los pacientes con cáncer.
MX2021013938A 2015-04-15 2017-10-11 Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer. MX2021013938A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2015/058212 WO2016165765A1 (en) 2015-04-15 2015-04-15 Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis

Publications (1)

Publication Number Publication Date
MX2021013938A true MX2021013938A (es) 2022-01-04

Family

ID=52829110

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017013074A MX2017013074A (es) 2015-04-15 2016-04-13 Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer.
MX2021013938A MX2021013938A (es) 2015-04-15 2017-10-11 Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017013074A MX2017013074A (es) 2015-04-15 2016-04-13 Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer.

Country Status (15)

Country Link
US (3) US10927413B2 (es)
EP (1) EP3283644B1 (es)
JP (3) JP6976855B2 (es)
KR (2) KR20220086708A (es)
CN (1) CN107873061B (es)
AU (1) AU2016249784B2 (es)
CA (1) CA2982390A1 (es)
ES (1) ES2787708T3 (es)
HK (1) HK1246829A1 (es)
IL (3) IL305880A (es)
MA (1) MA42974A (es)
MX (2) MX2017013074A (es)
SG (1) SG11201708270YA (es)
WO (2) WO2016165765A1 (es)
ZA (1) ZA201705936B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016165765A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
CN108330180A (zh) * 2017-10-25 2018-07-27 广州和康医疗技术有限公司 一种对fcgr3a位点进行基因型检测的方法及试剂盒
EP3792363A4 (en) * 2018-01-23 2022-01-12 Excellen Medical Technology Co., Ltd. METHOD AND KIT FOR IDENTIFYING THE STATE OF LUNG CANCER
AU2019232762B2 (en) 2018-03-08 2023-11-16 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
WO2020228806A1 (zh) * 2019-05-16 2020-11-19 齐鲁制药有限公司 针对密蛋白18a2的抗体及其应用
CN112133369B (zh) * 2020-08-26 2023-09-22 吴安华 基于活性氧评估肿瘤患者预后性的系统以及药物敏感性评价与改善方法
CN116926198A (zh) * 2023-09-15 2023-10-24 臻和(北京)生物科技有限公司 检测胃癌组织Claudin18.2蛋白阳性的方法、装置、设备和存储介质

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
AU3942202A (en) 2000-11-30 2002-06-11 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
ES2744275T3 (es) 2002-10-17 2020-02-24 Genmab As Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple
CN103209696B (zh) * 2010-04-21 2016-02-24 文蒂雷克斯药品公司 增强抗体依赖性细胞的细胞毒性的方法
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2016165765A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis

Also Published As

Publication number Publication date
IL305880A (en) 2023-11-01
US10927413B2 (en) 2021-02-23
KR20170138431A (ko) 2017-12-15
EP3283644B1 (en) 2020-04-01
MX2017013074A (es) 2018-03-15
JP2023040269A (ja) 2023-03-22
US20180073077A1 (en) 2018-03-15
CN107873061B (zh) 2022-09-13
IL296503B1 (en) 2023-10-01
RU2017139489A3 (es) 2019-11-18
ES2787708T3 (es) 2020-10-16
SG11201708270YA (en) 2017-11-29
MA42974A (fr) 2018-08-22
IL254086B2 (en) 2023-04-01
HK1246829A1 (zh) 2018-09-14
JP7217327B2 (ja) 2023-02-02
IL296503A (en) 2022-11-01
KR20220086708A (ko) 2022-06-23
JP2018512146A (ja) 2018-05-17
WO2016165765A1 (en) 2016-10-20
NZ736368A (en) 2021-09-24
US11732308B2 (en) 2023-08-22
IL296503B2 (en) 2024-02-01
EP3283644A1 (en) 2018-02-21
WO2016166124A1 (en) 2016-10-20
KR102409933B1 (ko) 2022-06-17
AU2016249784B2 (en) 2021-03-11
ZA201705936B (en) 2019-06-26
JP6976855B2 (ja) 2021-12-08
US20210324472A1 (en) 2021-10-21
IL254086A0 (en) 2017-10-31
US20240110247A1 (en) 2024-04-04
RU2017139489A (ru) 2019-05-15
BR112017018775A2 (pt) 2018-04-17
AU2016249784A1 (en) 2017-11-02
CA2982390A1 (en) 2016-10-20
JP2022023226A (ja) 2022-02-07
IL254086B (en) 2022-12-01
CN107873061A (zh) 2018-04-03

Similar Documents

Publication Publication Date Title
MX2021013938A (es) Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer.
MX2020008976A (es) Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
WO2011146568A8 (en) Predicting response to a her inhibitor
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2013006392A (es) Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
MX2017004526A (es) Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.
BR112014024017A8 (pt) Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
BR112017012142A2 (pt) método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
EA201890598A3 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
MX2018005867A (es) Integracion de las caracteristicas tumorales con el indice de cancer de mama.
MX2023007706A (es) Nanoparticulas para su uso como vacuna terapeutica.
TW201613587A (en) Medical treatments based on anamorelin
WO2013096776A3 (en) Radioactive compositions and methods for their therapeutic use
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2017014540A (es) Biomarcadores para una terapia combinada que comprende lenvatinib y everolimus.
WO2015181555A8 (en) Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent
MX2018009274A (es) Cancer.
BR112018011203A2 (pt) terapia de combinação para câncer
UA96591U (uk) Спосіб прогнозування зрощення перелому